Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID July 2, 2013 HIV Vaccine and Future Strategies.

Slides:

Advertisements

Similar presentations

Telling Time; Telling the Truth Engaging communities as stakeholders (and partners) in HIV vaccine R&D Mitchell Warren AVAC 2 July 2013 IAS Symposia Session:

Advertisements

Pox-Protein Public-Private Partnership (P5)

State of the Field Exploring 2015’s Top Ten List for the HIV Prevention Research Field Manju Chatani, Stacey Hannah, Mitchell Warren Thursday, January.

Immune Responses to HIV

What is a Vaccine? What Is A Vaccine? A vaccine is a substance that teaches the body’s immune system to recognize and protect against a disease caused.

HIV-VACCINES. HIV - Vaccines  Vaccine development remains priority of AIDS research   Best hope for protection against HIV infection.

What can we learn from diverse spectrum of HIV/SIV infections? Françoise BARRÉ-SINOUSSI Regulation of Retroviral Infections Unit Department of Virology.

How well are we doing in preventing HIV and how can we do better?

The World’s Biggest Minority Left Behind: National HIV-Responses Need to and Can Include Disability Towards a UNAIDS Disability Strategy Ruben Mayorga.

Immune Strategies for HIV Prevention

Blocviroc – an innovative treatment for HIV/AIDS Steve English Development Head, Antivirals.

AVAC Global Advocacy for HIV Prevention AIDS Vaccines: The basics May 2015.

Discovery of New Antibodies Against HIV A Case Study of a Global Partnership Prof. Omu Anzala Program Director Kenya AIDS Vaccine Initiative (KAVI) Department.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.

Dr Himani. Foams or creams that people can use in vagina or rectum during sex to prevent transmission Currently, there is no vaccine to prevent HIV. This.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/25/2011) Jerry P. Weir, Ph.D., Director.

Partnerships in Promoting Innovation and Managing Risk Scientific and Financial Innovation in AIDS Vaccines International AIDS Vaccine Initiative Labeeb.

Community Representation Structure. Site Coordinating Centers (SCC) Community Advisory Boards (CABs) Leadership Level Cross-Network Level Network Level.

Assessing the Response to Hepatitis B Immunizations in HIV-Positive Adults: Results from the 550 Clinic cohort study Camila Calderon 1, Anupama Raghuram.

Prior to exposure Point of transmission After infection Male and female condoms Antiretroviral therapy (mother-to- child) Post exposure prophylaxis (PEP)

RV 144: The Thai Phase III Trial and Development of a Globally-Effective, Multi-Clade HIV Vaccine HIV Vaccine: Quo Vadis AIDS July 2010 Dr. Merlin.

Established in late 1999 Scientific/clinical resources Ethics committees Regulatory body TT

The HVTN is supported by National Institute of Allergy and Infectious Diseases (NIAID). Panel 5: Current HIV Vaccine Research Clinical Research James Kublin,

Myron S. Cohen, MD Associate Vice Chancellor Director, Institute for Global Health The University of North Carolina.

Katharine Kripke, Ph.D. Assistant Director, Vaccine Research Program, Division of AIDS, NIAID AIDS Vaccine 2011 Journalist Training Program September 11,

What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,

Vaccine Quo Vadis? 20 July 2010 Alan Bernstein, O.C., Ph.D. Executive Director, Global HIV Vaccine Enterprise.

AIDS Vaccines: the basics CindraFeuer AVAC: Global Advocacy for HIV Prevention 20 April 2010 The HIV Research Catalyst Forum Baltimore, Maryland April.

INVESTING TO END THE AIDS EPIDEMIC: A NEW ERA FOR HIV RESEARCH & DEVELOPMENT HIV VACCINES WORKING GROUP & MICROBICIDES RESOURCE TRACKING E. Donaldson 1,

Advanced BioScience Laboratories

Towards an antibody-based HIV vaccine

Human clinical trial of DNA-MVA HIV vaccine candidate begins A Phase I study, called RV262, recently began to evaluate a combination DNA prime/MVA vector.

IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.

Thorny Issues in HIV Vaccine Trials Saul Walker Policy Advisor IAVI.

1 GROUPWORK (2) Most impactful next steps for adolescent trials: HIV vaccines Consultation on ethical-legal complexities in adolescent HIV vaccine & microbicide.

25 Years of HIV Vaccine Research: What have we accomplished? José Esparza MD, PhD Senior Advisor on HIV Vaccines Global Health Program The Search for an.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/22/2010) Jerry P. Weir, Ph.D., Director.

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE ALVAC-vCP1521 plus AIDSVAX B/E CRF01_AE (Clade E) -based HIV vaccines Phase 3 Trial in Thailand.

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee Nathan.

CATEGORY: VACCINES & THERAPEUTICS HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK HIV-1 Vaccines © The copyright for this work resides.

MHRP  The views expressed are those of the authors and should not be construed to represent the positions of the U.S. Army or the Department of Defense.

HVTN 702: A pivotal phase 2b/3 multi-site, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALVAC-HIV.

Vaccines and Microbicides Rebekah Webb, AVAC STOPAIDS All Members Meeting: Re-prioritising Prevention London, 12 th May 2016.

AVAC Global Advocacy for HIV Prevention HIV Vaccines: The basics May 2016.

04/19/ Projected effectiveness of mass HIV vaccination with multi-dose regimens to be tested in South Africa Peter Gilbert Dobromir Dimitrov Christian.

HIV Vaccines: The Basics

HIV-1 Vaccines Shokouh Makvandi-Nejad, University of Oxford, UK

Driving Future Success with Current Investments in HIV Research

Immune Responses to HIV

MOAX03 Chris Beyrer MD, MPH

Non-ARV Based Interventions to Combat HIV/AIDS: New Insights and Initiatives Yves Lévy Inserm, VRI.

IAS 2017 PARIS July 23rd, 2017.

HIV Vaccine Trials Network

HIV Vaccines: The Basics

Annual Research Day 17 April 2015

Behavioral and Social Science in Biomedical HIV Research

Antibody Mediated Prevention: HVTN 703/HPTN 081 Update

HIV Vaccine Development

? Neutralizing Antibodies: Research pathways in 2013 and beyond

Long-term data from APPROACH study

مقدمه ای بر مهارت های زندگی

Why we should ‘shock and kill’

Platforms of Protection for adolescent girls/young women

Percolating HIV Px Pipeline

Rectal Gels for PrEP Are They an Option?

Will There Be a Vaccine to Protect Against the Hepatitis C Virus?

Keep control: Elite and post-treatment controllers

Understanding Vaccine Partial Efficacy

Immunologic strategies for HIV-1 remission and eradication

HIV Vaccine Research and Development Pipeline: 2019 Supplement

Presentation transcript:

Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID July 2, 2013 HIV Vaccine and Future Strategies

This session will review past HIV vaccine efforts, as well as novel viral vectors and advances in the design of vaccines to induce neutralizing antibodies. A panel will discuss options to accelerate the development of a much needed HIV vaccine. ALVAC pox-based prime boost programme (RV144) Punnee Pitisuttithum, Thailand State of the art findings on HIV vaccines Glenda Gray, South Africa B cell response to vaccine candidates; antibody-based approaches Dennis Burton, United States Issues of engagement with populations at risk in HIV vaccine trials Mitchell Warren, United States Debate on future HIV vaccine strategies, including T response/other immune responses to vaccines Marcus Altfeld, United States Dennis Burton, United States Glenda Gray, South Africa Punnee Pitisuttithum, Thailand Mitchell Warren, United States

HIV Vaccine Efficacy Trials NOTE: Phambili (HVTN 503) began to explore a regime similar to STEP in South Africa (not included). No